Noven Patent-Cliff Exposure & CMS Drug Spending Portfolio

Noven (US): 4 reconciled FDA prescription therapies (16.9% 2025 to 2030 cliff risk), $21.0M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure16.9%
Primary Portfolio LOE Date2030-01-01
2024 CMS Total Public Spend$21.0M
2024 Medicare Part D Spend$7.0M
2024 Medicaid Spend$14.0M
California HCAI SB 17 Filings4 WAC filings (max 16.8% 2-yr change)